» Articles » PMID: 28706904

Malignant Peritoneal Mesothelioma: a Review

Overview
Journal Ann Transl Med
Date 2017 Jul 15
PMID 28706904
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Mesothelioma is a malignancy of serosal membranes. It is most commonly encountered in the visceral pleura with the second most common location in the peritoneum. The diagnosis is very rare and has been linked to toxic exposure to industrial pollutants, especially asbestos. Malignant peritoneal mesothelioma (MPM) commonly presents with diffuse, extensive spread throughout the abdomen with rare metastatic spread beyond the abdominal cavity. Due to its rarity and nonspecific symptoms, it is usually diagnosed late when the disease burden is extensive. Because pleural mesothelioma is more common than MPM, most research has been on the pleural variant and extrapolated for MPM. While treatment advances have been made for MPM, the disease is universally fatal from either abdominal complications secondary to the spread of disease or starvation. Untreated, the life expectancy is less than a year. Cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) has become the mainstay of therapy with systemic therapies still being developed. We will review the epidemiology of MPM and discuss diagnostic and treatment strategies.

Citing Articles

Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.

Xue C, Dong Z, Tan K, Zhang X, Yu Y, Wang S Oncol Lett. 2025; 29(4):187.

PMID: 40070788 PMC: 11894505. DOI: 10.3892/ol.2025.14933.


Diagnostic Differentiation Between Two Rare Entities-Metastatic Peritoneal Mesothelioma With Duodenal Involvement and Duodenal Synovial Sarcoma: A Case Report.

Zwetkoff B, Maluf-Filho F, Venco F, Blasbalg R, de Mello E, de Almeida Barros M Cureus. 2024; 16(11):e74764.

PMID: 39735025 PMC: 11682729. DOI: 10.7759/cureus.74764.


Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions.

Karunakaran K, Ganapathiraju M BJC Rep. 2024; 2(1):42.

PMID: 39516360 PMC: 11524009. DOI: 10.1038/s44276-024-00062-w.


Antigen targeting and anti-tumor activity of a novel anti-CD146 Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma.

Lindland K, Malenge M, Li R, Wouters R, Bonsdorff T, Juzeniene A Sci Rep. 2024; 14(1):25941.

PMID: 39472474 PMC: 11522520. DOI: 10.1038/s41598-024-76778-z.


Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.

Sakura K, Kuroyama M, Shintani Y, Funaki S, Atagi S, Kadota Y Cancer Immunol Immunother. 2024; 73(12):243.

PMID: 39358654 PMC: 11447170. DOI: 10.1007/s00262-024-03815-1.


References
1.
Yan T, Popa E, Brun E, Cerruto C, Sugarbaker P . Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg. 2006; 93(12):1536-42. DOI: 10.1002/bjs.5377. View

2.
Sugarbaker P . Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park). 2004; 18(1):51-9. View

3.
Salemis N, Tsiambas E, Gourgiotis S, Mela A, Karameris A, Tsohataridis E . Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation. J Dig Dis. 2007; 8(4):216-21. DOI: 10.1111/j.1751-2980.2007.00309.x. View

4.
Boffetta P . Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2006; 18(6):985-90. DOI: 10.1093/annonc/mdl345. View

5.
Henley S, Larson T, Wu M, Antao V, Lewis M, Pinheiro G . Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health. 2013; 19(1):1-10. PMC: 4406225. DOI: 10.1179/2049396712Y.0000000016. View